Literature DB >> 22565371

Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity.

Padmanee Sharma, Christopher Logothetis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565371     DOI: 10.1038/nrurol.2012.103

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

Review 1.  The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications.

Authors:  Anna Maria Di Giacomo; Maurizio Biagioli; Michele Maio
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  Management of the febrile neutropenic cancer patient: lessons from 40 years of study.

Authors:  E J Bow
Journal:  Clin Microbiol Infect       Date:  2005-10       Impact factor: 8.067

4.  Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.

Authors:  A van Elsas; A A Hurwitz; J P Allison
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

Review 5.  Side effects of corticosteroid therapy.

Authors:  A L Buchman
Journal:  J Clin Gastroenterol       Date:  2001-10       Impact factor: 3.062

6.  Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Alfons J M van den Eertwegh; Jurjen Versluis; H Pieter van den Berg; Saskia J A M Santegoets; R Jeroen A van Moorselaar; Tim M van der Sluis; Helen E Gall; Thomas C Harding; Karin Jooss; Israel Lowy; Herbert M Pinedo; Rik J Scheper; Anita G M Stam; B Mary E von Blomberg; Tanja D de Gruijl; Kristen Hege; Natalie Sacks; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

7.  Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:  Ravi A Madan; Mahsa Mohebtash; Philip M Arlen; Matteo Vergati; Myrna Rauckhorst; Seth M Steinberg; Kwong Y Tsang; Diane J Poole; Howard L Parnes; John J Wright; William L Dahut; Jeffrey Schlom; James L Gulley
Journal:  Lancet Oncol       Date:  2012-02-10       Impact factor: 41.316

8.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

Review 9.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.

Authors:  Padmanee Sharma; Klaus Wagner; Jedd D Wolchok; James P Allison
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

  10 in total
  3 in total

1.  Don't run before you can walk.

Authors:  Licia Rivoltini; Andrea Marrari; Chiara Castelli; Sergio Villa; Riccardo Valdagni
Journal:  Nat Rev Urol       Date:  2012-09-25       Impact factor: 14.432

Review 2.  Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?

Authors:  Andrew L Laccetti; Sumit K Subudhi
Journal:  Curr Opin Urol       Date:  2017-11       Impact factor: 2.309

Review 3.  Trial watch: Peptide-based vaccines in anticancer therapy.

Authors:  Lucillia Bezu; Oliver Kepp; Giulia Cerrato; Jonathan Pol; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-09-06       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.